Aspirin The Anti-Cancer Drug? New Evidence From 3 Studies

Many people already take a daily low-dose aspirin as a heart drug, but three new British studies suggest it may prevent and possibly even treat cancer. The studies, published in The Lancet and The Lancet Oncology journals, add to mounting evidence of the drug’s anti-cancer effects, reports BBC News. Previous studies have found that daily aspirin reduces the long-term risk of death from cancer, particularly colorectal cancer, but people needed to take the drug for about 10 years to get …

The Takeaway: Gingrich Pushes Private Social Security Accounts In Debate; Rethinking Aspirin

New Gingrich once again touted private Social Security accounts at last night’s Republican presidential debate in South Carolina. The televised debate was spirited but lacking in substance.

The Takeaway: Aspirin Cuts Bowel Cancer Risk; GPS Shoes For Patients With Dementia

Patients who took 600 mg of aspirin daily for two years were 63 percent less likely to get colorectal cancer than those who took a placebo. New GPS sneakers were designed mainly with Alzheimer’s and dementia patients in mind.

The Takeaway: Taking Aspirin? Don’t Stop; Longevity Study; Prehistoric Grandparents

Aspirin wards off heart attack–just don’t stop taking it, study warns. Researchers tracked people ages 50 to 84 and found patients with a history of heart disease who had recently stopped low-dose aspirin were 63 percent more likely to have a heart attack. “Even stopping aspirin for 15 days was associated with the short-term risk.”

Can an Aspirin a Day Be Bad for Your Health?

Check out this AARP Bulletin piece on how new guidelines on aspirin are saying that not everyone should be taking the drug every day, as it may pose serious health risks: The aspirin-a-day controversy erupted publicly in March when a 10-year study of nearly 30,000 adults ages 50 to 75 without known heart disease found that a daily aspirin didn’t offer any discernible protection. The group taking aspirin had cardiovascular disease at the same rate as those taking a placebo. …